TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05900622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced postoperative braking and bed rest time.Lower extremity on the puncture side with a 2-hour brake+Get out of bed after 4 hours
Description: Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Significantly reduce postoperative braking and bed rest time.No braking of the lower limb on the side of the puncture+Get out of bed after 2 hours
Description: Braking time is defined as the time from the start of postoperative lying down until the patient sits up in bed and can move the lower limbs Bed rest is the time from when the patient is lying down to when they are on the floor after the procedure, but it has been identified as the most difficult part of post-vascular puncture intervention care
Study: NCT04657822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: Concentrate for solution for infusion for Intravenous use
Study: NCT05204862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Intravenously administered
Study: NCT05877690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% Injectable Solution
Description: Patient will be received the drug intrathecal
Study: NCT06476132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Belumosudil
Description: Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.
Study: NCT05877690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine Hydrochloride 2% Injection
Description: Patient will be received the drug intrathecal
Study: NCT05694884

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: ASLAN004
Study: NCT06409390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: 75 mg/m2 once every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: 600 mg/m2 once every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: 5.4 mg/kg once every 21 days for 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: 10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: 600 mg orally daily 21 days on, 7 days off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg by mouth twice daily
Study: NCT06128044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-012
Description: CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-012
Description: CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion
Study: NCT06457191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intermittent theta-burst stimulation transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation transcranial magnetic stimulation
Description: Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous theta-burst stimulation transcranial magnetic stimulation
Description: Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 40 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation transcranial magnetic stimulation
Description: Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 40 seconds.
Study: NCT05046496

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Intra-arterial digital subtraction angiography
Description: Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed
Study: NCT06001502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality distraction therapy
Description: The VR device simulates a 3-dimensional virtual enviroment, seeking to immerse the user in virtual surroundings
Study: NCT04954664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allograft particles hydrated with rhPDGF
Description: Allograft particles should be hydrated with GEM21S for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allograft particles hydrated in a conventional way with saline.
Description: Allograft particles should be hydrated with saline for 20 minutes prior to grafting. The graft sites will be covered with a resorbable barrier membrane
Study: NCT05199610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aumolertinib
Description: A single dose of 55-mg EQ143 tablet will be administered in the morning on Day 1, and participants will remain for 5 days (4 nights) in the study center for collection of blood samples and safety monitoring. Participants will attend outpatient follow-up visits on Days 5, 6, 8, and 9 for additional blood sampling and safety assessments.
Study: NCT06253390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive training
Description: Metacognitive training therapy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: control
Description: management technique as usual
Study: NCT06071065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist counselling
Description: Counselling session with Pharmacist about disease and medication therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist counselling
Description: Counselling session with Pharmacist about disease and medication therapy.
Study: NCT00939601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Counseling
Study: NCT05161208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline 0.6mg/ml) Nasal Spray
Description: Intranasal delivery of OC-01 nasal spray twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Intranasal delivery of Placebo (vehicle) nasal spray twice daily (BID)
Study: NCT05927025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand K-files
Description: It is used for cleaning and shaping root canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand K-files
Description: It is used for cleaning and shaping root canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand K-files
Description: It is used for cleaning and shaping root canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand K-files
Description: It is used for cleaning and shaping root canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand K-files
Description: It is used for cleaning and shaping root canals.
Study: NCT06318858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplement
Description: Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iron supplement
Description: Group 1: 12.5 mg daily iron syrup supplementation from 6-9 months old
Study: NCT05655936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Health Doula Intervention Program
Description: The intervention group will be given a smart blood pressure cuff and a smart scale to monitor weight. The intervention group will receive support provided a postpartum doula until 8-12 weeks postpartum. The doula will provide individualized support during this time, and after 8-12 weeks, women will transition to a doula-moderated support group for the remainder of the study. The intervention group will continue to receive blood pressure and weight monitoring for the remainder of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care includes enrollment into a clinical 6-week home-based blood pressure monitoring program with text messaging support which includes receiving a home blood pressure cuff. Women in the intervention group will be offered the same support as the usual care group, and in addition will receive the intervention and supplies.
Study: NCT05434403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Description: vagus nerve electrical stimulation through ear skin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham vagus nerve stimulation
Description: sham vagus nerve electrical stimulation through ear skin
Study: NCT05694988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efferon CT
Description: Efferon CT (JSC Efferon, Moscow, RF) is a device for extracorporeal blood purification by direct hemoperfusion. Detoxification is carried out by sorption of cytokines and other products of endogenous intoxication with a molecular size of up to 55 kDa.
Study: NCT06296823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated jetlag protocol
Description: 16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated jetlag protocol
Description: 16 hours of wakefulness and an 8 hour scheduled sleep opportunity in a simulated jetlag protocol where you will go to bed and awaken earlier than usual.
Study: NCT05973227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of the TRIDENT system
Description: usage of Trident System v1.0, just before the final resection, to obtain some images of the tissue oxygenation.
Study: NCT06313047

Intervention type: DRUG
Intervention: Doxorubicin
Description: each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Study: NCT06089122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Patients with primary immunodeficiency will switch to Shu Yang IVIG and optimize the posology to IgG 300 to 600 mg every 21 or 28 days in a run-in period of 2 to 6 administrations, aiming at keeping the IgG trough levels above 5 g/L. At Visit 4, at least 20 patients will perform the PK assessment, collecting additional blood samples.
Study: NCT05591248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRR
Description: Eligible patients meeting the inclusion criteria and signed a consent, will have 3x/week the guided rehabilitation session with the VR-tool (with a maximum of 9 VRR-sessions).
Study: NCT06290089

Intervention type: OTHER
Group type: OTHER
Intervention: Enterotoxigenic E. coli (ETEC) strain
Description: Challenge strain
Study: NCT05448547

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy or surgery
Description: see arm/ group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: initial observation
Description: see arm/ group description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone therapy
Description: androgen depression therapy (ADT) by either LHRH agonist or antagonist or androgen monotherapy
Study: NCT06178614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-87890387
Description: JNJ-87890387 will be administered.
Study: NCT06245746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)
Description: UCMSC-Exo will be infused intravenously.
Study: NCT05201781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilta-cel
Description: Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.
Study: NCT04750655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin (Topical)
Description: We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Topical)
Description: We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (Topical)
Description: We are using moxifloxacin as indicated and as intended for use as an antibiotic during surgery. Frequency of postoperative antibiotics dependent on group randomization.
Study: NCT05542290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsular tension ring implantation
Description: Capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: No capsular tension ring implantation
Description: No capsular tension ring implantation during phacoemulsification lens extraction and intraocular lens implantation combined with goniosynechialysis in included angle closure patients.
Study: NCT06407284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Produce Prescription Group
Description: Participants will receive 16 produce bags, each containing approximately 50 servings of F\&V. The produce bags will be assembled by Brighter Bites at school sites using donated produce and delivered to houses using DoorDash. F\&V bags will be distributed to families every 2 weeks for 16 distributions (over approximately 32 weeks). Participants will also receive nutrition education, including MyPlate.gov's Start Simple App for adolescents, and a Virtual Culinary Medicine Program for parents; these nutrition education programs are theory-driven, tailored to diverse populations, and proven to support behavior change.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants in this group will be selected from de-identified Electronic Health Record (EHR) provided by Legacy Community Health with a 1-to-1 match to the intervention group participant's demographic characteristics and Medicaid eligibility.
Study: NCT04735016

Intervention type: DEVICE
Intervention: DiamondTemp™ Ablation System
Description: A cardiac ablation will be performed using the DiamondTemp™ Ablation System.
Study: NCT04672889

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 1 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Babyguard® Breast Milk Probiotics
Description: consume 1 sachet per day for 1 months
Study: NCT06308094

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT
Description: Pre-ablation CT is clinically acquired in patients undergoing catheter ablation. This study entails additional acquisition of the left ventricle to assess extracellular volume (ECV)
Study: NCT04970511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BBAT (Basic Body Awareness Therapy)
Description: The group I: BBAT Face-to-Face Training (60 min) will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online BBAT training
Description: The group II: Online BBAT training (60 min) will be provided.
Study: NCT05088889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered IV over 30 minutes at a dose of 360mg every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Ipilimumab administered IV over 30 minutes at 1 mg/kg every 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy
Description: Three fractions of 8 Gy, treated on alternate days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose irradiation
Description: a single fraction of 2Gy will be given to the metastatic lesions at first progression
Study: NCT06121011

Intervention type: BIOLOGICAL
Intervention: Cipaglucosidase alfa
Description: Enzyme Replacement Therapy (ERT) via intravenous infusion

Intervention type: DRUG
Intervention: Miglustat
Description: Participants received ATB200 co-administered with AT2221 (Miglustat)

Intervention type: BIOLOGICAL
Intervention: Alglucosidase alfa or Avalglucosidase alfa
Description: Patients prescribed other commercially available ERT after local regulatory approval

Intervention type: OTHER
Intervention: Untreated
Description: Patients who are not currently receiving any medical therapy for Pompe disease.
Study: NCT04868838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 1800 mg administered by subcutaneous injection by manual push over approximately 3-5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses.
Study: NCT06260709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC6019-0001
Description: Intravenous NNC6019-0001 every 4 weeks added to the standard of care until Week 140.
Study: NCT05755711

Intervention type: DEVICE
Intervention: Shockwave Medical Coronary IVL System
Description: Coronary Intravascular Lithotripsy (IVL)
Study: NCT05542498

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Training is focused on learning and applying the principles of R.A.I.N. (Recognize, Allow, Investigate, Non-identify) in the context of physics learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Training is focused on learning and applying relaxation practices (e.g., progressive muscle relaxation, guided imagery) in the context of physics learning.
Study: NCT05908786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.
Study: NCT05029583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine screening
Description: routine screening for advanced NASH

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physician-driven screening
Description: physician-driven screening for advanced NASH
Study: NCT05708157

Intervention type: DRUG
Intervention: concomitant intranasal antihistamine and corticosteroid
Description: concomitant intranasal administration with antihistamine and corticosteroid
Study: NCT06482294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: One arm is a combination of salbutamol and fluticason as a rescue medication (anti-inflammatory rescue medication). The second arm is salbutamol only as a rescue medication (non-anti-inflammatory rescue medication).
Study: NCT05367856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide combined with BEAM
Description: Chidamide: 30mg po D-7,D-4,D-1 and D+3 Carmustine: 300mg/m2 ivgtt D-7 Etoposide: 100mg/m2/d ivgtt q12h D-6-D-3 Cytarabine: 200mg/m2/d ivgtt q12h D-6-D-3 Melphalan: 140mg/m2 ivgtt D-2